GT-02287 Trial Moves Forward: A Potential Step Toward Slowing Parkinson’s Progression

Gain Therapeutics has completed enrollment—three months ahead of schedule—for a Phase 1b clinical trial testing the safety and tolerability of a new oral treatment called GT-02287 in people with Parkinson’s disease. The study, which includes up to 20 participants aged 30–85 in Australia, is ongoing until the end of July. Participants were diagnosed within the past seven years and may or may not carry a mutation in the GBA1 gene, a known risk factor for Parkinson’s. 🧬 How Does GT-02287 Work? GT-02287 is designed to reactivate a key enzyme (GCase) that helps cells break down and recycle waste. In people with GBA1 mutations, GCase doesn’t work properly, which can lead to the harmful buildup of proteins like alpha-synuclein, one of the hallmarks of Parkinson’s disease. By restoring enzyme function, the treatment may help prevent nerve cell damage and potentially slow or stop disease progression. 🐭 Promising Results in the Lab In preclinical studies (in lab models and animals), GT-02287: ✅ Boosted GCase activity ✅ Reduced toxic protein buildup ✅ Protected brain cells ✅ Improved movement and memory in a mouse model of Parkinson’s ✅ Lowered levels of a brain injury biomarker (neurofilament light chain) 🧠 Can It Reach the Brain? Yes. In an earlier trial with healthy volunteers, GT-02287 was found to be: ✔️ Safe and well tolerated ✔️ Able to cross the blood-brain barrier (essential for brain treatment) ✔️ Effective in increasing GCase activity by about 53% 📅 What’s Happening Now All participants in the Phase 1b trial are receiving daily oral doses for 90 days, and researchers are monitoring safety, how the drug behaves in the body, and its impact on blood and cerebrospinal fluid (CSF) biomarkers. Thanks to early enrollment, all participants are expected to complete treatment by the end of the year, which will speed up analysis of results. 🌱 Why This Matters While still early, GT-02287 represents a hopeful step toward treatments that target the root causes of Parkinson’s, not just the symptoms. More research is needed, but this could one day lead to personalized, gene-informed care for people living with Parkinson’s.